Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2023

Open Access 01-12-2023 | Melanoma | Review

Current status of skin cancers with a focus on immunology and immunotherapy

Authors: Mahsa Khayyati Kohnehshahri, Aila Sarkesh, Leila Mohamed Khosroshahi, Zanyar HajiEsmailPoor, Ali Aghebati-Maleki, Mehdi Yousefi, Leili Aghebati-Maleki

Published in: Cancer Cell International | Issue 1/2023

Login to get access

Abstract

Skin cancer is one of the most widespread cancers, with a significant global health effect. UV-induced DNA damage in skin cells triggers them to grow and proliferate out of control, resulting in cancer development. Two common types of skin cancer include melanoma skin cancer (MSC) and non-melanoma skin cancer (NMSC). Melanoma is the most lethal form of skin cancer, and NMSC includes basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and other forms. The incidence of skin cancer is increasing in part owing to a demographic shift toward an aging population, which is more prone to NMSC, imposing a considerable financial strain on public health services. The introduction of immunostimulatory approaches for cancer cell eradication has led to significant improvements in skin cancer treatment. Over the last three decades, monoclonal antibodies have been used as powerful human therapeutics besides scientific tools, and along with the development of monoclonal antibody production and design procedures from chimeric to humanized and then fully human monoclonal antibodies more than 6 monoclonal antibodies have been approved by the food and drug administration (FDA) and have been successful in skin cancer treatment. In this review, we will discuss the epidemiology, immunology, and therapeutic approaches of different types of skin cancer,
Literature
1.
Fuchs E, Raghavan S. Getting under the skin of epidermal morphogenesis. Nat Rev Genet. 2002;3(3):199–209.PubMed
2.
Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol. 2004;4(3):211–22.PubMedPubMedCentral
3.
Scherer D, Kumar R. Genetics of pigmentation in skin cancer–a review. Mutat Res. 2010;705(2):141–53.PubMed
4.
Gloster HM Jr, Brodland DG. The epidemiology of skin cancer. Dermatol Surg. 1996;22(3):217–26.PubMed
5.
Silverberg E, Boring CC, Squires TS. Cancer statistics, 1990. CA Cancer J Clin. 1990;40(1):9–26.PubMed
6.
Johnson TM, et al. Clinical and histologic trends of melanoma. J Am Acad Dermatol. 1998;38(5 Pt 1):681–6.PubMed
7.
Einspahr JG, et al. Chemoprevention of human skin cancer. Crit Rev Oncol Hematol. 2002;41(3):269–85.PubMed
8.
Weir K, et al. Oropharyngeal aspiration and pneumonia in children. Pediatr Pulmonol. 2007;42(11):1024–31.PubMed
9.
Chummun S, McLean NR. The management of malignant skin cancers. Surg Infect (Larchmt). 2017;35(9):519–24.
10.
Perrotta RE, Giordano M, Malaguarnera M. Non-melanoma skin cancers in elderly patients. Crit Rev Oncol Hematol. 2011;80(3):474–80.PubMed
11.
12.
Green A, et al. Skin cancer in a subtropical Australian population: incidence and lack of association with occupation. The Nambour study group. Am J Epidemiol. 1996;144(11):1034–40.PubMed
13.
Sorkhabi AD, et al. Vitamin supplementation as a potential adjunctive therapeutic approach for COVID-19: biological and clinical plausibility. J Basic Clin Physiol Pharmacol. 2022;33(1):55–77.
14.
Silpa SR, Chil V. A review on skin cancer. Int Res J Pharm. 2013;4(8):83–8.
15.
Mukhtar H, Elmets CA. Photocarcinogenesis: mechanisms, models and human health implications. Photochem Photobiol. 1996;63(4):356–7.PubMed
16.
Chang NB, et al. Skin cancer incidence is highly associated with ultraviolet-B radiation history. Int J Hyg Environ Health. 2010;213(5):359–68.PubMed
17.
Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B. 2001;63(1–3):8–18.PubMed
18.
Zafiropoulos A, et al. Human herpes viruses in non-melanoma skin cancers. Cancer Lett. 2003;198(1):77–81.PubMed
19.
Yu SH, Bordeaux JS, Baron ED. The immune system and skin cancer. Adv Exp Med Biol. 2014;810:182–91.PubMed
20.
Chen T, et al. Cyclosporin A impairs dendritic cell migration by regulating chemokine receptor expression and inhibiting cyclooxygenase-2 expression. Blood. 2004;103(2):413–21.PubMed
21.
Gerlini G, Romagnoli P, Pimpinelli N. Skin cancer and immunosuppression. Crit Rev Oncol Hematol. 2005;56(1):127–36.PubMed
22.
Leffell DJ. The scientific basis of skin cancer. J Am Acad Dermatol. 2000;42(1 Pt 2):18–22.PubMed
23.
Nataraj AJ, Trent JC 2nd, Ananthaswamy HN. p53 gene mutations and photocarcinogenesis. Photochem Photobiol. 1995;62(2):218–30.PubMed
24.
25.
Ben Ayed I, et al. Mucosal human papillomavirus detection and TP53 immunohistochemical expression in non-melanoma skin cancer in Tunisian patients. J Cutan Pathol. 2019;46(8):591–8.PubMed
26.
Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J Invest Dermatol. 2016;136(6):1161–71.PubMed
27.
Perera E, et al. Incidence and prevalence of non-melanoma skin cancer in Australia: a systematic review. Australas J Dermatol. 2015;56(4):258–67.PubMed
28.
Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ. 2005;331(7515):481.PubMedPubMedCentral
29.
Nakayama K. Growth and progression of melanoma and non-melanoma skin cancers regulated by ubiquitination. Pigment Cell Melanoma Res. 2010;23(3):338–51.PubMed
30.
31.
Qadir MI. Skin cancer: etiology and management. Pak J Pharm Sci. 2016;29(3):999–1003.PubMed
32.
Kumar N, Saxena YK. Two cases of rare presentation of basal cell and squamous cell carcinoma on the hand. Indian J Dermatol Venereol Leprol. 2002;68(6):349–51.PubMed
33.
Marghoob AA. Skin cancers and their etiologies. Semin Cutan Med Surg. 2011;30(4 Suppl):S1-5.PubMed
34.
Marks R. An overview of skin cancers incidence and causation. Cancer. 1995;75(2 Suppl):607–12.PubMed
35.
Møller R, Reymann F, Hou-Jensen K. Metastases in dermatological patients with squamous cell carcinoma. Arch Dermatol. 1979;115(6):703–5.PubMed
36.
Lear JT, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018;32(3):372–81.PubMed
37.
Kaldor J, et al. Non-melanoma skin cancer: ten years of cancer-registry-based surveillance. Int J Cancer. 1993;53(6):886–91.PubMed
38.
Green CL, Khavari PA. Targets for molecular therapy of skin cancer. Semin Cancer Biol. 2004;14(1):63–9.PubMed
39.
Brantsch KD, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008;9(8):713–20.PubMed
40.
Serrano H, et al. Incidence of nonmelanoma skin cancer in new hampshire and vermont. J Am Acad Dermatol. 1991;24(4):574–9.PubMed
41.
Langley RGB, B R, Mihm MC, Fitzpatrick TB, Sober AJ. Dermatology in general medicine. New York: McGraw-Hill Press; 2003.
42.
Emmons KM, et al. Skin cancer education and early detection at the beach: a randomized trial of dermatologist examination and biometric feedback. J Am Acad Dermatol. 2011;64(2):282–9.PubMed
43.
Caforio AL, et al. Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy. Circulation. 2000;102(3):222–7.
44.
Ulrich C, et al. Cutaneous precancers in organ transplant recipients: an old enemy in a new surrounding. Br J Dermatol. 2003;149(Suppl 66):40–2.PubMed
45.
Mendez JC, Paya CV. Kaposi’s Sarcoma and transplantation. Herpes. 2000;7(1):18–23.PubMed
46.
Penn I, First MR. Merkel’s cell carcinoma in organ recipients: report of 41 cases. Transplantation. 1999;68(11):1717–21.PubMed
47.
Katalinic A, Kunze U, Schäfer T. Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). Br J Dermatol. 2003;149(6):1200–6.PubMed
48.
Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol. 2002;146(Suppl 61):1–6.PubMed
49.
Leiter U, Garbe C. Epidemiology of melanoma and nonmelanoma skin cancer–the role of sunlight. Adv Exp Med Biol. 2008;624:89–103.PubMed
50.
Fransen M, et al. Non-melanoma skin cancer in Australia. Med J Aust. 2012;197(10):565–8.PubMed
51.
Wu X, Elkin EE, Marghoob AA. Burden of basal cell carcinoma in USA. Future Oncol. 2015;11(22):2967–74.PubMed
52.
Mudigonda T, et al. The economic impact of non-melanoma skin cancer: a review. J Natl Compr Canc Netw. 2010;8(8):888–96.PubMed
53.
Qureshi AA, et al. Host risk factors for the development of multiple non-melanoma skin cancers. J Eur Acad Dermatol Venereol. 2013;27(5):565–70.PubMed
54.
Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005;353(21):2262–9.PubMed
55.
Leiter U, Eigentler T, Garbe C. Epidemiology of skin cancer. Adv Exp Med Biol. 2014;810:120–40.PubMed
56.
Rastrelli M, et al. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 2014;28(6):1005–11.PubMed
57.
58.
59.
Abdayem R, Haftek M. The epidermal barrier. Ann Dermatol Venereol. 2018;145(4):293–301.PubMed
60.
Tremante E, et al. A melanoma immune response signature including human Leukocyte Antigen-E. Pigment Cell Melanoma Res. 2014;27(1):103–12.PubMed
61.
Nickoloff BJ, Turka LA. Immunological functions of non-professional antigen-presenting cells: new insights from studies of T-cell interactions with keratinocytes. Immunol Today. 1994;15(10):464–9.PubMed
62.
Black AP, et al. Human keratinocyte induction of rapid effector function in antigen-specific memory CD4+ and CD8+ T cells. Eur J Immunol. 2007;37(6):1485–93.PubMed
63.
64.
Schmitt D. Cutaneous immune system. C R Seances Soc Biol Fil. 1994;188(3):207–21.PubMed
65.
66.
Tay SS, et al. The skin-resident immune network. Curr Dermatol Rep. 2014;3(1):13–22.PubMed
67.
Yousef, H., et al., Histology, Skin Appendages, in StatPearls. 2021, StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC.: Treasure Island (FL).
68.
Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10.PubMed
69.
Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006;6(11):836–48.PubMed
70.
Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15(9):540–55.PubMed
71.
Meftahpour, V., et al., Prognostic significance and therapeutic potentials of immune checkpoints in osteosarcoma. Excli j, 2022;21:250–68.
72.
73.
Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene. 2008;27(45):5932–43.PubMed
74.
Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res. 2011;71(7):2411–6.PubMed
75.
76.
77.
78.
79.
Gogoi D, Chiplunkar SV. Targeting gamma delta T cells for cancer immunotherapy: bench to bedside. Indian J Med Res. 2013;138(5):755–61.PubMedPubMedCentral
80.
Vesely MD, et al. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235–71.PubMed
81.
Crespo J, et al. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol. 2013;25(2):214–21.PubMedPubMedCentral
82.
83.
Sun JC, Lanier LL. Natural killer cells remember: an evolutionary bridge between innate and adaptive immunity? Eur J Immunol. 2009;39(8):2059–64.PubMedPubMedCentral
84.
Podojil JR, Miller SD. Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy. Immunol Rev. 2009;229(1):337–55.PubMedPubMedCentral
85.
Contardi E, et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer. 2005;117(4):538–50.PubMed
86.
Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010;127(4):759–67.PubMed
87.
Gobert M, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009;69(5):2000–9.PubMed
88.
Patrinely JR, Dewan AK, Johnson DB. The role of anti-PD-1/PD-L1 in the treatment of skin cancer. BioDrugs. 2020;34(4):495–503.PubMedPubMedCentral
89.
Vazirabad AF, et al. Silencing of SiX-4 enhances the chemosensitivity of melanoma cells to Cisplatin. Pathol Res Pract. 2022;240:154194.PubMed
90.
Mohamed Khosroshahi, L., et al., Immune checkpoints and reproductive immunology: Pioneers in the future therapy of infertility related Disorders? International Immunopharmacology, 2021;99:107935.PubMed
91.
Mogenet A, et al. Predictable toxicities with futures immunotherapies or combinations. Bull Cancer. 2020;107(10):1069–78.PubMed
92.
Fourcade J, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010;207(10):2175–86.PubMedPubMedCentral
93.
Sorkhabi AD, et al. Cancer combination therapies by silencing of CTLA-4, PD-L1, and TIM3 in osteosarcoma. IUBMB Life. 2022;74(9):908–17.PubMed
94.
95.
Ma B, Anandasabapathy N. Immune checkpoint blockade and skin toxicity pathogenesis. J Investig Dermatol. 2022;142(3):951–9.PubMed
96.
Aghebati-Maleki, L., et al., Future prospects of monoclonal antibodies as magic bullets in Immunotherapy. Human antibodies, 2013;22:9–13.
97.
Luu C, Khushalani NI, Zager JS. Intralesional and systemic immunotherapy for metastatic melanoma. Expert Opin Biol Ther. 2016;16(12):1491–9.PubMed
98.
Morgado-Carrasco D, et al. Immunotherapy for advanced skin cancer. Actas Dermosifiliogr. 2019;110(1):53–6.PubMed
99.
Papadopoulos KP, et al. REGN2810: A fully human anti-PD-1 monoclonal antibody, for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)—Initial safety and efficacy from expansion cohorts (ECs) of phase I study. J Clin Oncol. 2017;35(15):9503–9503.
100.
Stevenson ML, et al. Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab. JAMA Dermatol. 2017;153(4):299–303.PubMed
101.
Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013;19(19):5300–9.PubMed
102.
Raedler LA. Keytruda (pembrolizumab): first PD-1 inhibitor approved for previously treated unresectable or metastatic melanoma. Am Health Drug Benefits. 2015;8:96–100.PubMedPubMedCentral
103.
Raedler LA. Opdivo (Nivolumab): second PD-1 inhibitor receives FDA approval for unresectable or metastatic melanoma. Am Health Drug Benefits. 2015;8:180–3.PubMedPubMedCentral
104.
Ahmed SR, et al. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma. Expert Rev Clin Pharmacol. 2019;12(10):947–51.PubMed
105.
Wollina U, Tchernev G, Lotti T. Chimeric monoclonal antibody cetuximab targeting epidermal growth factor-receptor in advanced non-melanoma skin cancer. Open Access Maced J Med Sci. 2018;6(1):152–5.PubMed
106.
Wollina U. Cetuximab in non-melanoma skin cancer. Expert Opin Biol Ther. 2012;12(7):949–56.PubMed
107.
Ansary TM, et al. Immunotherapy for the treatment of squamous cell carcinoma: potential benefits and challenges. Int J Mol Sci. 2022;23(15):8530.PubMedPubMedCentral
108.
Fujimura T. Stromal factors as a target for immunotherapy in melanoma and non-melanoma skin cancers. Int J Mol Sci. 2022;23(7):4044.PubMedPubMedCentral
109.
Daei Sorkhabi A, et al. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. Front Immunol. 2023;14:1113882.PubMedPubMedCentral
110.
Simon B, Uslu U. CAR-T cell therapy in melanoma: a future success story? Exp Dermatol. 2018;27(12):1315–21.PubMed
111.
Daei Sorkhabi A, et al. The basis and advances in clinical application of cytomegalovirus-specific cytotoxic T cell immunotherapy for glioblastoma multiforme. Front Oncol. 2022;12:818447.PubMedPubMedCentral
112.
Agnarsdóttir M, Popova S, Alafuzoff I. Expression of CMV protein pp65 in cutaneous malignant melanoma. PLoS ONE. 2019;14(10):e0223854.PubMedPubMedCentral
113.
Ko JH, et al. Inhibitory effects of interferon-gamma plasmid DNA on DMBA-TPA induced mouse skin carcinogenesis. Cancer Gene Ther. 2011;18(9):646–54.PubMed
114.
Samlowski WE, et al. Intrathecal administration of interleukin-2 for meningeal carcinomatosis due to malignant melanoma: sequential evaluation of intracranial pressure, cerebrospinal fluid cytology, and cytokine induction. J Immunother Emphasis Tumor Immunol. 1993;13(1):49–54.PubMed
115.
Rezaei T, et al. Strategies in DNA vaccine for melanoma cancer. Pigment Cell Melanoma Res. 2021;34(5):869–91.PubMed
116.
Ji J, et al. DC vaccine generated by ALA-PDT-induced immunogenic apoptotic cells for skin squamous cell carcinoma. Oncoimmunology. 2016;5(6):e1072674.PubMed
117.
118.
Shomali N, et al. Dysregulation of survivin-targeting microRNAs in autoimmune diseases: new perspectives for novel therapies. Front Immunol. 2022;13:839945.PubMedPubMedCentral
119.
Zhang H, et al. MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model. Vaccine. 2016;34(24):2648–55.PubMed
120.
Killock D. Skin cancer: T-VEC oncolytic viral therapy shows promise in melanoma. Nat Rev Clin Oncol. 2015;12(8):438.PubMed
121.
Guy GP Jr, et al. Prevalence and costs of skin cancer treatment in the U.S., 2002–2006 and 2007–2011. Am J Prev Med. 2015;48(2):183–7.PubMed
122.
Singh S, et al. Monoclonal antibodies: a review. Curr Clin Pharmacol. 2018;13(2):85–99.PubMed
123.
Simões MCF, Sousa JJS, Pais A. Skin cancer and new treatment perspectives: a review. Cancer Lett. 2015;357(1):8–42.PubMed
Metadata
Title
Current status of skin cancers with a focus on immunology and immunotherapy
Authors
Mahsa Khayyati Kohnehshahri
Aila Sarkesh
Leila Mohamed Khosroshahi
Zanyar HajiEsmailPoor
Ali Aghebati-Maleki
Mehdi Yousefi
Leili Aghebati-Maleki
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2023
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-023-03012-7

Other articles of this Issue 1/2023

Cancer Cell International 1/2023 Go to the issue

Research

Polyamine metabolism patterns characterized tumor microenvironment, prognosis, and response to immunotherapy in colorectal cancer

Research

Triple negative breast cancer metastasis is hindered by a peptide antagonist of F11R/JAM‑A protein

Research

In vitro and in vivo analyses on anti-NSCLC activity of apatinib: rediscovery of a new drug target V600E mutation

Research

Heat shock protein 27 deficiency promotes ferrous ion absorption and enhances acyl-Coenzyme A synthetase long-chain family member 4 stability to promote glioblastoma cell ferroptosis

Research

Prognosis-related molecular subtyping in head and neck squamous cell carcinoma patients based on glycolytic/cholesterogenic gene data

Review

Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits